FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1484-1491

  Lei, Dapeng ^a,c,d   Sturgis, Erich M ^a   Wang, Li E ^a   Liu, Zhensheng ^a   Zafereo, Mark E ^b   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Shandong University   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND; PROTEIN FASLG; UNCLASSIFIED DRUG; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; ADOLESCENT; DISEASE COURSE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SECOND CANCER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 77953303585     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0030     Document Type: Article

References (44)

1. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer 2007;110: 1429-35.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
3. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449-56.
4. Kotwall C, Razack MS, Sako K, Rao U. Multiple primary cancers in squamous cell cancer of the head and neck. J Surg Oncol 1989;40: 97-9.
5. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994;86:131-7.
6. Do KA, Johnson MM, Lee JJ, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004;101:2837-42.
7. León X, Del PradoVenegas M, Orús C, Kolañczak K, García J, Quer M. Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 2005;262:905-9.
8. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86:1681-4.
9. Cloos J, Leemans CR, van der Sterre MLT, Kuik DJ, Snow GB, Braakhuis BJM. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2000;9:713-7.
10. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996;313:716-21.
11. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res 2009;2: 617-24.
12. Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 2005;115: 2221-31.
13. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 2006;106:2636-44.
14. Li F, Sturgis EM, Zafereo ME, et al. p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. Int J Cancer 2009; 125:2660-5.
15. Zafereo ME, Sturgis EM, Aleem S, Chaung K, Wei Q, Li G. Glutathione S-transferase polymorphisms and risk of second primary malignancy after index squamous cell carcinoma of the head and neck. Cancer Prev Res 2009;2:432-9.
16. Zafereo ME, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G. Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 2009;30:997-1002.
17. Zörnig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001;1551:F1-37.
18. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
19. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
20. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol 1994;6:279-89.
21. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
22. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
23. Lai HC, Lin WY, Lin YW, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005;99:113-8.
24. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;2:479-84.
25. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28: 1067-73.
26. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-6.
27. Yang S, Miao XP, Zhang XM, et al. Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi 2005;85:2132-5 (in Chinese).
28. Muraki Y, Yoshioka C, Tateishi A, Fukuda J, Haneji T, Kobayashi N. Localization of Fas antigen in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1999;37:37-40. (Pubitemid 29095044)
29. Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer 1997;33:1860-4.
30. Zhang Z, Wang LE, Sturgis EM, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:5596-602.
31. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
32. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30.
33. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancerbinding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-8.
34. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 1932;51:1358.
35. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fasligand induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
36. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/CD95) ligand expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
37. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-25.
38. Reichman E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12:309-15.
39. Kripple P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96: 1478-9.
40. Ueda M, Terai Y, Kanda K, et al. Fas gene promoter-670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006;16: 179-82.
41. Sun T, Zhou Y, Li H, et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005;202:967-74.
42. Do KA, Johnson MM, Doherty DA, et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 2003; 14:131-8.
43. Hashibe M, Ritz B, Le AD, Li G, Sankaranarayanan R, Zhang ZF. Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett 2005;220:185-95.
44. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-62.